JP2017526706A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526706A5
JP2017526706A5 JP2017513199A JP2017513199A JP2017526706A5 JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5 JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049213 external-priority patent/WO2016040498A1/en
Publication of JP2017526706A publication Critical patent/JP2017526706A/ja
Publication of JP2017526706A5 publication Critical patent/JP2017526706A5/ja
Pending legal-status Critical Current

Links

JP2017513199A 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物 Pending JP2017526706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048759P 2014-09-10 2014-09-10
US62/048,759 2014-09-10
US201562146794P 2015-04-13 2015-04-13
US62/146,794 2015-04-13
PCT/US2015/049213 WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017526706A JP2017526706A (ja) 2017-09-14
JP2017526706A5 true JP2017526706A5 (enExample) 2018-10-18

Family

ID=55459522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513199A Pending JP2017526706A (ja) 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物

Country Status (6)

Country Link
US (2) US10428029B2 (enExample)
EP (1) EP3193603A4 (enExample)
JP (1) JP2017526706A (enExample)
AU (1) AU2015315167A1 (enExample)
CA (1) CA2960274A1 (enExample)
WO (1) WO2016040498A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP2017528460A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド
WO2016204006A1 (ja) 2015-06-17 2016-12-22 住友化学株式会社 有害節足動物防除剤
CU20210018A7 (es) * 2018-09-21 2021-10-12 Novartis Ag Compuestos de isoxazol-3-carboxamida
CN109879868B (zh) * 2019-03-07 2022-04-22 南通大学 含2-芳基噁唑结构的吡唑酰胺类化合物的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
DE19930075A1 (de) * 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
GB0017518D0 (en) * 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
AU2002338334B8 (en) * 2001-04-03 2008-09-18 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B antagonists
CA2449249A1 (en) * 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
CA2589773A1 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
KR20100007956A (ko) * 2007-05-03 2010-01-22 화이자 리미티드 나트륨 채널 조절제로서의 2-피리딘 카복스아마이드 유도체
WO2008137834A2 (en) * 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
EP2528925B1 (en) * 2010-01-29 2017-07-05 Hanmi Science Co., Ltd. THIENO[3,2-d]PYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY ON PROTEIN KINASES
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
US9919129B2 (en) * 2012-12-18 2018-03-20 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
EP2968266B1 (en) * 2013-03-15 2019-05-01 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) compounds in the treatment and/or prevention of cardiovascular diseases
MX2017002986A (es) 2014-09-10 2017-10-24 Epizyme Inc Compuestos de piperidina sustituidos.
AU2015315171A1 (en) 2014-09-10 2017-03-16 Epizyme, Inc. Substituted cyclohexylamine compounds
US20170247326A1 (en) 2014-09-10 2017-08-31 Epizyme, Inc. Substituted Pyrrolidine Carboxamide Compounds
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP2017528460A (ja) 2014-09-10 2017-09-28 エピザイム インコーポレイテッド 不可逆的smyd阻害剤としてのイソオキサゾールカルボキサミド
US20170253601A1 (en) * 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds

Similar Documents

Publication Publication Date Title
JP2017526706A5 (enExample)
JP2017528464A5 (enExample)
JP2016514695A5 (enExample)
JP2017527577A5 (enExample)
JP2017528460A5 (enExample)
JP2017538659A5 (enExample)
JP2019514950A5 (enExample)
CN106660974A (zh) 含氨磺酰基的1,2,5‑噁二唑类衍生物、其制备方法及其在医药上的应用
JP2017527576A5 (enExample)
CN103402519B (zh) 肿瘤治疗剂
JP2020515571A5 (enExample)
JP2017510641A5 (enExample)
CY1118730T1 (el) Παραγωγα πυριδινης ως αναστολεις της αναδιαταχθεισας κατα την διαρκεια διαλοιμωξης (ret) κινασης
JP2013064024A5 (enExample)
IL272697B2 (en) A polymorphic form of TG02
IL312936A (en) 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo-[1,2-A] pyrido [3,4-E] pyrimidine-5(1H)-one, analogs and salts thereof, and methods of use for therapy
JP2016521280A5 (enExample)
JP2017528461A5 (enExample)
RU2014101626A (ru) Полиморфы 2-амид 1-({4-метил-5-[2-(2, 2, 2-трифтор-1, 1-диметил-этил)-пиридин-4-ил]тиазол-2-ил}амида) (s)-пирролидин-1, 2-дикарбоновой кислоты
HRP20211877T1 (hr) Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
JPWO2021188948A5 (enExample)
RU2017124371A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина
JP2016106092A (ja) 組合せ
JP2020506884A5 (enExample)
CN108463462A (zh) 苯二氮*类作为溴结构域抑制剂